LU91083I2 - Bortezomib ou un des ester pharmaceutiquement acceptables, optionnellement sous forme d'un sel pharmaceutiquement acceptable-Velcade. - Google Patents

Bortezomib ou un des ester pharmaceutiquement acceptables, optionnellement sous forme d'un sel pharmaceutiquement acceptable-Velcade.

Info

Publication number
LU91083I2
LU91083I2 LU91083C LU91083C LU91083I2 LU 91083 I2 LU91083 I2 LU 91083I2 LU 91083 C LU91083 C LU 91083C LU 91083 C LU91083 C LU 91083C LU 91083 I2 LU91083 I2 LU 91083I2
Authority
LU
Luxembourg
Prior art keywords
pharmaceutically acceptable
velcade
bortezomib
optionally
acceptable salt
Prior art date
Application number
LU91083C
Other languages
English (en)
Other versions
LU91083I9 (fr
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26987313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91083(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of LU91083I2 publication Critical patent/LU91083I2/fr
Publication of LU91083I9 publication Critical patent/LU91083I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
LU91083C 1994-10-28 2004-06-09 Bortezomib ou un des ester pharmaceutiquement acceptables, optionnellement sous forme d'un sel pharmaceutiquement acceptable-Velcade. LU91083I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33052594A 1994-10-28 1994-10-28
US08/442,581 US6083903A (en) 1994-10-28 1995-05-16 Boronic ester and acid compounds, synthesis and uses
PCT/US1995/014117 WO1996013266A1 (fr) 1994-10-28 1995-10-27 Composes d'esters et d'acides boroniques, leur synthese et leurs utilisations

Publications (2)

Publication Number Publication Date
LU91083I2 true LU91083I2 (fr) 2004-08-09
LU91083I9 LU91083I9 (fr) 2018-12-28

Family

ID=26987313

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91083C LU91083I2 (fr) 1994-10-28 2004-06-09 Bortezomib ou un des ester pharmaceutiquement acceptables, optionnellement sous forme d'un sel pharmaceutiquement acceptable-Velcade.

Country Status (24)

Country Link
US (16) US6083903A (fr)
EP (4) EP0788360B3 (fr)
JP (1) JP3717934B2 (fr)
KR (1) KR100398944B1 (fr)
CN (2) CN1305475C (fr)
AT (3) ATE314378T1 (fr)
AU (1) AU710564B2 (fr)
CA (2) CA2203936C (fr)
CH (1) CH0788360H1 (fr)
CY (1) CY2484B1 (fr)
DE (5) DE122004000025I1 (fr)
DK (3) DK1312609T3 (fr)
ES (3) ES2254803T3 (fr)
FI (2) FI114801B (fr)
FR (1) FR04C0014I2 (fr)
IL (5) IL115790A (fr)
LU (1) LU91083I2 (fr)
MX (1) MX9703063A (fr)
NL (1) NL300151I2 (fr)
NO (2) NO310558B1 (fr)
NZ (2) NZ337211A (fr)
PT (3) PT788360E (fr)
TW (1) TW318850B (fr)
WO (1) WO1996013266A1 (fr)

Families Citing this family (307)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
FR2758329B1 (fr) * 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
US6271199B2 (en) 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
US6221888B1 (en) * 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
WO1999015183A1 (fr) * 1997-09-25 1999-04-01 Proscript Inc. INIHIBITEURS DE PROTEASOME, INHIBITEURS DES VOIES DE L'UBIQUITINE OU AGENTS ENTRAVANT L'ACTIVATION DE NF-λB PAR LES VOIES DE l'UBIQUITINE PROTEASOME POUR TRAITER DES MALADIES INFLAMMATOIRES ET DES MALADIES AUTOIMMUNES
CN1163594C (zh) * 1997-09-29 2004-08-25 尖端医疗有限公司 体外造血细胞的刺激
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
CA2219867A1 (fr) * 1997-10-31 1999-04-30 Jiangping Wu Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique
DE19802450A1 (de) * 1998-01-23 1999-07-29 Hoechst Marion Roussel De Gmbh Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
EP0982317A1 (fr) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs bivalents de protéasome
US6613541B1 (en) * 1998-10-20 2003-09-02 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
US6492333B1 (en) * 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6649593B1 (en) * 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
US20040039129A1 (en) * 2000-08-16 2004-02-26 Hall Dennis G. Non-pressurized methods for the preparation of conjugrated solid supports for boronic acids
US6919382B2 (en) 2000-08-31 2005-07-19 The Governors Of The University Of Alberta Preparation and uses of conjugated solid supports for boronic acids
ATE338564T1 (de) * 2000-10-12 2006-09-15 Viromics Gmbh Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
CA2435124A1 (fr) * 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation de composes d'acide boronique
CA2447909C (fr) 2001-05-21 2011-04-05 Alcon, Inc. Utilisation d'inhibiteurs de proteasome pour traiter des secheresses de l'oeil
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6933290B2 (en) 2001-05-30 2005-08-23 Novartis Ag 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
JPWO2003033507A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
US7524883B2 (en) 2002-01-08 2009-04-28 Eisai R&D Management Co., Ltd. Eponemycin and epoxomicin analogs and uses thereof
WO2003077928A1 (fr) * 2002-03-12 2003-09-25 Ariad Pharmaceuticals, Inc. Analogues de peptides et utilisations
EA007099B1 (ru) 2002-03-13 2006-06-30 Янссен Фармацевтика Н. В. Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы
ATE521592T1 (de) 2002-03-13 2011-09-15 Janssen Pharmaceutica Nv Histone-deacetylase-inhibitoren
MXPA04008795A (es) * 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Derivados de piperazinilo, piperidinilo y morfolino como novedosos inhibidores de la desacetilasa de histona.
US7446109B2 (en) * 2002-03-13 2008-11-04 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
EP1492545B1 (fr) * 2002-04-05 2010-09-15 ViroLogik GmbH Agent de traitement d'infections par flaviviridae
US7514579B2 (en) * 2002-06-13 2009-04-07 Johns Hopkins University Boronic chalcone derivatives and uses thereof
AU2003248921A1 (en) * 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy
DK1536777T3 (da) * 2002-08-14 2007-06-04 Janssen Pharmaceutica Nv Anvendelse af NF-KB-inhibitorer til behandling af mastitis
US20050119226A1 (en) * 2003-09-09 2005-06-02 Trigen Limited Methods for synthesizing organoboronic compounds and products thereof
US20050176651A1 (en) * 2002-09-09 2005-08-11 Trigen Limited Peptide boronic acids useful in making salts thereof
US7371729B2 (en) * 2002-09-09 2008-05-13 Trigen Limited Boronic acid salts useful in parenteral formulations
EP1396269A1 (fr) * 2002-09-09 2004-03-10 Trigen Limited Sels d'acide boronique des metaux multivalents et leur utilisation dans la préparation de médicaments pour le traitement de la thrombose
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
US20050282757A1 (en) * 2002-09-09 2005-12-22 Trigen Limited Peptide boronic acid compounds useful in anticoagulation
PL374700A1 (pl) * 2002-09-20 2005-10-31 Alcon, Inc. Zastosowanie inhibitorów syntezy cytokiny do leczenia zespołu suchego oka
ES2542328T3 (es) 2002-12-06 2015-08-04 Millennium Pharmaceuticals, Inc. Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
CN100341880C (zh) * 2003-02-13 2007-10-10 上海仁虎制药股份有限公司 新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
US20070110785A1 (en) * 2003-07-03 2007-05-17 Eugene Tedeschi Medical devices with proteasome inhibitors for the treatment of restenosis
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AU2004288231A1 (en) * 2003-11-05 2005-05-19 Palingen, Inc. Enhanced B cell cytotoxicity of CDIM binding antibody
US20060052390A1 (en) * 2003-12-24 2006-03-09 Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
RU2379315C2 (ru) * 2004-02-23 2010-01-20 Трастиз Оф Тафтс Колледж Ингибиторы дипептидилпептидазы iv
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
AU2016202747B2 (en) * 2004-03-30 2017-11-23 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
RS65253B1 (sr) * 2004-03-30 2024-03-29 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
EP1745064B1 (fr) 2004-04-15 2011-01-05 Proteolix, Inc. Composés pour l'inhibition d'une enzyme de protéasome
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
CN102875642A (zh) 2004-05-10 2013-01-16 普罗特奥里克斯公司 用于酶抑制的化合物
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
CN101087756B (zh) 2004-07-23 2011-04-06 纽阿达有限责任公司 肽酶抑制剂
NZ552865A (en) 2004-07-28 2009-09-25 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
CA2584515A1 (fr) 2004-10-20 2006-04-27 Proteolix, Inc. Composes pour inhibition d'enzymes
WO2006052641A2 (fr) 2004-11-05 2006-05-18 Palingen, Inc. Fragilisation de la membrane cellulaire induite par anticorps
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
AU2006207325B2 (en) 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
WO2006081371A2 (fr) * 2005-01-27 2006-08-03 Research Development Foundation Therapie de combinaison avec des composes triterpenoides et des inhibiteurs de proteasome
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
PT3424932T (pt) * 2005-02-16 2021-05-19 Anacor Pharmaceuticals Inc Boronoftalidas para utilização terapêutica
US7589066B2 (en) * 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
AU2006242446A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
ES2553178T3 (es) 2005-05-18 2015-12-04 Janssen Pharmaceutica N.V. Derivados sustituidos de aminopropenil piperidina o morfolina como nuevos inhibidores de histona deacetilasa
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
PT1888123E (pt) * 2005-06-08 2013-03-13 Janssen Biotech Inc Uma terapêutica celular para a degeneração ocular
WO2007002972A2 (fr) * 2005-07-06 2007-01-11 Biodevelops Pharma Entwicklung Gmbh Utilisation d'un compose permettant d'ameliorer l'expression des proteines membranaires sur la surface d'une cellule
EP1752467A1 (fr) 2005-08-10 2007-02-14 4Sc Ag Inhibiteurs de la proliferation de cellules cancereuses, de cellules t, et de keratinocytes
US7531517B2 (en) 2005-08-10 2009-05-12 4Sc Ag Inhibitors of cancer cell, T-cell and keratinocyte proliferation
US20070059382A1 (en) * 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
ES2628620T3 (es) 2005-11-09 2017-08-03 Onyx Therapeutics, Inc. Compuesto para inhibición de enzimas
US20090221488A1 (en) * 2005-12-08 2009-09-03 Wood Kenneth W Certain Compositions and Methods of Treatment
JP2009526751A (ja) 2005-12-30 2009-07-23 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
JP5225104B2 (ja) * 2006-01-19 2013-07-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新しい、ヒストンデアセチラーゼのインヒビターとしてのアミノフェニル誘導体
EP1979327A1 (fr) * 2006-01-19 2008-10-15 Janssen Pharmaceutica, N.V. Dérivés de pyridine et de pyrimidine en tant qu'inhibiteurs d'histone désacétylase
DK1979326T3 (da) 2006-01-19 2013-01-07 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
CA2635015C (fr) * 2006-01-19 2014-06-03 Janssen Pharmaceutica N.V. Derive d'indolyl-alkyl-amino substitues en tant qu'inhibiteurs d'histone desacetylase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
RU2508113C2 (ru) * 2006-02-16 2014-02-27 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных средств
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
WO2007143600A2 (fr) * 2006-06-05 2007-12-13 Incyte Corporation Inhibiteurs de la sheddase combinés avec des substances immunothérapeutiques se liant à cd30 destinés au traitement de maladies associées à cd30
CA2657213C (fr) 2006-06-19 2017-01-03 Proteolix, Inc. Peptides epoxycetones pour l'inhibition de proteasomes
KR101489947B1 (ko) * 2006-09-15 2015-02-04 얀센 파마슈티카 엔.브이. 프로테아좀 억제제와 배합하여, ｉ－형 및 ｉｉｂ－형 히스톤 데아세틸라아제에 결합 활성을 나타내는 히스톤 데아세틸라아제 억제제
MX2009002926A (es) * 2006-09-15 2009-03-31 Janssen Pharmaceutica Nv Combinaciones de inhibidores de histona desacetilasa especificos de clase-i con inhibidores del proteasoma.
WO2008044045A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
EP2073803B1 (fr) 2006-10-12 2018-09-19 Astex Therapeutics Limited Combinaisons pharmaceutiques
AU2007221966A1 (en) * 2006-12-08 2008-06-26 Centenary Institute Of Cancer Medicine And Cell Biology Assay for response to proteasome inhibitors
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
US9096832B2 (en) 2007-07-31 2015-08-04 Lifescan, Inc. Differentiation of human embryonic stem cells
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
SI2170396T1 (sl) 2007-08-03 2017-04-26 Summit (Oxford) Limited Kombinacije zdravil za zdravljenje duchennove mišične distrofije
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
KR20140042933A (ko) 2007-08-06 2014-04-07 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
US20100226597A1 (en) * 2007-09-12 2010-09-09 Dr. Reddy's Laboratories Limited Bortezomib and process for producing same
US20090076031A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bortezomib
KR20100088664A (ko) 2007-10-04 2010-08-10 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
CN107574142B (zh) * 2007-11-27 2021-07-06 生命扫描有限公司 人胚胎干细胞的分化
CN101220048B (zh) * 2007-12-14 2012-08-15 江苏先声药物研究有限公司 ZnCl2催化下的蒎烷二醇酯的制备方法
UY31545A1 (es) 2007-12-20 2009-08-03 Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
CA2959401C (fr) 2008-02-21 2021-12-07 Centocor Ortho Biotech Inc. Procedes, plaques a surface modifiee et compositions permettant la fixation, la culture et le detachement de cellules
KR20150065941A (ko) * 2008-03-06 2015-06-15 아나코르 파마슈티칼스 인코포레이티드 소염제로써 붕소가 함유된 소분자
WO2009140309A2 (fr) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
EA030685B1 (ru) * 2008-06-17 2018-09-28 Милленниум Фармасьютикалз, Инк. Способ получения соединения боронатного эфира
KR20180018839A (ko) 2008-06-30 2018-02-21 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
CN101638414B (zh) * 2008-07-30 2014-01-08 江苏先声药物研究有限公司 肽硼酸及其酯类化合物、制备方法及其用途
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
EP2348863A4 (fr) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Petites molécules contenant du bore
WO2010028005A1 (fr) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
US20110236428A1 (en) 2008-10-21 2011-09-29 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
CN102333862B (zh) * 2008-10-31 2018-04-27 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
ES2584053T3 (es) * 2008-11-20 2016-09-23 Janssen Biotech, Inc. Métodos y composiciones para la unión de células y cultivo en sustratos planos
MX356756B (es) 2008-11-20 2018-06-11 Centocor Ortho Biotech Inc Células madre pluripotentes en microportadores.
CN101747354B (zh) * 2008-12-04 2014-08-13 江苏先声药物研究有限公司 一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
PE20120052A1 (es) * 2008-12-17 2012-02-13 Anacor Pharmaceuticals Inc Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c][1,2]-oxaborol-1-ol
CA2748921A1 (fr) 2009-01-09 2010-08-12 Sun Pharma Advanced Research Company Limited Composition pharmaceutique
US20120190565A1 (en) 2009-02-20 2012-07-26 Pangea Biosciences, Inc. Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm
EP2405916B1 (fr) 2009-03-12 2018-02-07 Genentech, Inc. Combinaison de composés inhibiteurs de la phosphoinositide 3-kinase et d'agents chimiothérapeutiques pour le traitement de tumeurs malignes hématopoïétiques
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2010106135A1 (fr) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Utilisation combinée pour le traitement d'un carcinome ovarien
HRP20150948T1 (hr) 2009-03-24 2015-10-09 Janssen Pharmaceutica N.V. Biomarkeri za procjenjivanje perifernog neuropatskog odgovora na lijeäśenje sa inhibitorom proteazoma
WO2010117668A1 (fr) * 2009-03-30 2010-10-14 Cerulean Pharma Inc. Conjugués polymère-agent, particules, compositions et procédés d'utilisation apparentés
WO2010114768A1 (fr) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-épothilone, particules, compositions et procédés d'utilisation apparentés
WO2010114770A1 (fr) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-agent, particules, compositions et procédés d'utilisation apparentés
CA2763471A1 (fr) * 2009-05-27 2010-12-02 Cephalon, Inc. Polytherapie pour le traitement d'un myelome multiple
JP2012530116A (ja) 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法
EP2270019A1 (fr) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. Nouvelle voie de synthèse pour la préparation d'esters boronique alpha-aminé
CN101928329B (zh) * 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
EP2280016A1 (fr) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. Nouvelle voie de synthèse pour la préparation d'esters boroniques aminés via des Alk-1-ynes substitués
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
DE102009027754A1 (de) 2009-07-15 2011-05-05 Schubert, Ulrich, Dr. Verfahren zur Hemmung der Reifung von dendritischen Zellen
KR101785626B1 (ko) * 2009-07-20 2017-10-16 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
WO2011011300A2 (fr) 2009-07-20 2011-01-27 Centocor Ortho Biotech Inc. Différentiation de cellules souches embryonnaires humaines
JP5819826B2 (ja) 2009-07-20 2015-11-24 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の分化
US8343944B2 (en) * 2009-07-28 2013-01-01 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
WO2011019618A1 (fr) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore et utilisables en tant qu'agents antiprotozoaires
WO2011022502A1 (fr) 2009-08-18 2011-02-24 Georgetown University Compositions d'acide boronique et procédés se rapportant au cancer
US20110207701A1 (en) * 2009-08-19 2011-08-25 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011029802A1 (fr) 2009-09-08 2011-03-17 F. Hoffmann-La Roche Ag Composés de pyridin-3-yl-carboxamide 4-substitué et procédés d'utilisation
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
EP2305285A1 (fr) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Supports et procédés pour traiter les conditions ischémiques
RS55931B1 (sr) 2009-10-01 2017-09-29 Janssen Pharmaceutica Nv Inhibitori proteazoma za lečenje kancera
WO2011049971A1 (fr) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore comme agents antiprotozoaires
US20110212918A1 (en) * 2009-11-11 2011-09-01 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011060179A1 (fr) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Utilisation de peptides epoxycetones pour la suppression de la metastase
EP2516449A1 (fr) 2009-12-22 2012-10-31 Cephalon, Inc. Inhibiteurs du protéasome et leurs procédés de préparation, d'épuration et d'utilisation
AU2010333840B2 (en) 2009-12-23 2016-01-07 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
KR101773538B1 (ko) 2009-12-23 2017-08-31 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
WO2011090940A1 (fr) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Polymères à base de cyclodextrine pour administration thérapeutique
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
PH12012501686A1 (en) 2010-03-01 2020-10-19 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
MX2012010017A (es) * 2010-03-01 2012-10-01 Onyx Therapeutics Inc Compuestos de para la inhibicion de inmunoproteasomas.
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
WO2011116286A2 (fr) * 2010-03-18 2011-09-22 Innopharma, Llc Formulations stables à base de bortézomib
US8623911B2 (en) 2010-03-19 2014-01-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
US8513218B2 (en) * 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
AU2013204868B2 (en) * 2010-03-31 2016-10-13 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2012011604A (es) 2010-04-07 2013-02-27 Onyx Therapeutics Inc Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino.
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
CN102946879B (zh) 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
CN102884176B (zh) 2010-05-12 2017-09-05 詹森生物科技公司 人胚胎干细胞的分化
EP2571525A4 (fr) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions et procédés de traitement de maladies auto-immunes et autres
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
AU2011296383B2 (en) 2010-08-31 2016-03-10 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
RU2620938C2 (ru) 2010-08-31 2017-05-30 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
MX355077B (es) 2010-08-31 2018-04-03 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
CN108610356B (zh) 2010-09-07 2021-02-26 阿纳科制药公司 苯并氧杂硼杂环戊二烯衍生物用于治疗细菌感染
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
AU2011312264B2 (en) 2010-10-05 2015-07-02 Fresenius Kabi Usa, Llc Bortezomib formulations stabilised with boric acid
EP2627636B1 (fr) 2010-10-14 2015-09-02 Synthon BV Procédé pour la fabrication de bortézomib et des intermédiaires pour la procédé
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
TW201309303A (zh) * 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
US9272014B2 (en) 2011-03-29 2016-03-01 Texas Tech University System Galectin-3C combination therapy for human cancer
RU2569847C2 (ru) 2011-03-31 2015-11-27 Нанокэрриер Ко., Лтд. Фармацевтическая композиция, содержащая блок-сополимер, включающий соединение бороновой кислоты
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
MX2013015308A (es) * 2011-06-22 2014-05-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
US8481655B2 (en) 2011-07-27 2013-07-09 Wacker Chemical Corporation Copper complexes of amino-functional organosilicon compounds and their use
WO2013021032A1 (fr) 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Inhibiteurs d'histone désacétylase en combinaison avec des inhibiteurs du protéasome et la dexaméthasone
CA2844825A1 (fr) 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Procede de prediction pour le traitement du cancer
EP3199531A1 (fr) 2011-08-19 2017-08-02 Glaxo Group Limited Composés benzofuranes pour le traitement d'infections par le virus de l'hépatite c
EP4144354B1 (fr) 2011-08-30 2025-11-26 Trustees Of Tufts College Inhibiteurs de protéasome activés par fap utilisés pour traiter les tumeurs solides
CA2789539A1 (fr) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection de virus de la stomatite vesiculeuse recombinant exprimant des proteines hiv-1 en neutralisant largement les anticorps
EP2586461A1 (fr) 2011-10-27 2013-05-01 Christopher L. Parks Particules virales dérivées d'un virus enveloppé
PH12014500912A1 (en) 2011-10-28 2014-06-09 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013063496A1 (fr) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarqueurs de réponse aux inhibiteurs de nae
WO2013071142A1 (fr) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarqueurs de la sensibilité à des inhibiteurs du protéasome
JP6286358B2 (ja) 2011-11-11 2018-02-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
AU2012337721B2 (en) 2011-11-17 2015-12-10 Nanocarrier Co., Ltd. Block copolymer having phenylboronic acid group introduced therein, and use thereof
US9388386B2 (en) 2011-12-22 2016-07-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
WO2013110005A1 (fr) 2012-01-18 2013-07-25 Wisconsin Alumni Research Foundation Administration de médicament médiée par les boronate
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
EP2810066B1 (fr) 2012-01-24 2019-07-31 Millennium Pharmaceuticals, Inc. Méthodes de traitement du cancer
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
AU2013200903B2 (en) 2012-02-08 2015-05-14 Mcure Biosciences Inc. CDIM binding proteins and uses thereof
CA2866135A1 (fr) 2012-03-02 2014-09-06 Dr. Reddy's Laboratories Limited Compositions pharmaceutiques comprenant des composes acide boronique
US9434920B2 (en) 2012-03-07 2016-09-06 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
CA2784240C (fr) 2012-03-27 2014-07-08 Innopharma, Inc. Formulations stables a base de bortezomib
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
CN108103005A (zh) 2012-06-08 2018-06-01 詹森生物科技公司 人胚胎干细胞向胰腺内分泌细胞的分化
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2014011695A2 (fr) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Promédicaments d'inhibiteurs d'époxy cétone protéase peptidique
JP2013006855A (ja) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc プロテアソーム阻害剤
JP2015532915A (ja) * 2012-09-11 2015-11-16 シプラ・リミテッド ボルテゾミブの製造方法
EP2904115B1 (fr) 2012-10-01 2018-08-08 Millennium Pharmaceuticals, Inc. Biomarqueurs et procédés pour prédire la réponse vis-à-vis d'inhibiteurs et leurs utilisations
WO2014072985A1 (fr) 2012-11-06 2014-05-15 Natco Pharma Limited Nouveaux dérivés d'acide boronique an tant qu'agents anticancéreux
EP2919786A4 (fr) 2012-11-16 2016-06-01 Shilpa Medicare Ltd Procédé de préparation de bortézomib cristallin
WO2014097306A1 (fr) 2012-12-21 2014-06-26 Natco Pharma Limited Forme polymorphe stable et pure du bortézomib
ES2942484T3 (es) 2012-12-31 2023-06-01 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas usando reguladores de HB9
JP6529440B2 (ja) 2012-12-31 2019-06-12 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞への分化のためのヒト多能性細胞の懸濁及びクラスタリング
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
SG10201709338RA (en) 2012-12-31 2017-12-28 Janssen Biotech Inc Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
ZA201402789B (en) 2013-04-16 2015-11-25 Cipla Ltd Process for the preparation of bortezomib mannitol ester
EP2986290A4 (fr) 2013-04-19 2017-01-04 Thomas Jefferson University Methodes associees a la caveoline-1 pour le traitement d'un glioblastome par temozolomide
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
MX2016003979A (es) 2013-10-03 2016-06-15 Millennium Pharm Inc Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN104586776B (zh) * 2013-10-30 2017-05-17 扬子江药业集团上海海尼药业有限公司 以硼替佐米为活性成分的制剂及其制备方法
WO2015076359A1 (fr) * 2013-11-21 2015-05-28 国立大学法人北海道大学 Compose inhibiteur du proteasome
US10191033B2 (en) 2013-12-05 2019-01-29 The Broad Institute, Inc. Biomarkers for detecting pre-cachexia or cachexia and methods of treatment thereof
CA2930359C (fr) 2013-12-06 2022-03-01 Novartis Ag Schema posologique d'un inhibiteur de la phosphatidylinositol 3-kinase selectif de l'isoforme alpha
EP3102585B1 (fr) 2014-02-03 2021-05-19 Ohio State Innovation Foundation Esters d'acide boronique et leurs formulations pharmaceutiques
EP2910557A1 (fr) * 2014-02-20 2015-08-26 Ikerchem, S.L. Pyrrolidines tétrasubstitués énantiopures en tant qu'échafaudages pour inhibiteurs de protéasome et ses applications médicinales
WO2015170757A1 (fr) 2014-05-08 2015-11-12 国立大学法人 東京大学 Composition pharmaceutique
CN117821369A (zh) 2014-05-16 2024-04-05 詹森生物科技公司 小分子增强胰腺内分泌细胞中的mafa表达的用途
UY36132A (es) 2014-05-20 2015-11-30 Millennium Pharm Inc Métodos para terapia de cáncer
EP3177292B1 (fr) 2014-08-07 2020-11-25 Mayo Foundation for Medical Education and Research Composés et méthodes de traitement du cancer
CN107074885B (zh) * 2014-10-01 2020-11-27 默克专利股份公司 硼酸衍生物
WO2016110870A1 (fr) 2015-01-07 2016-07-14 Emcure Pharmaceuticals Limited Composition pharmaceutique de bortézomid
MA41505A (fr) 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
US20180243217A1 (en) 2015-03-17 2018-08-30 Leon-Nanodrugs Gmbh Nanoparticles comprising a stabilized boronic acid compound
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
WO2016184793A1 (fr) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de traitement de patients souffrant d'un adénocarcinome rénal métastatique résistant aux inhibiteurs du vegfr
WO2016205790A2 (fr) 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Composés spécifiques chiraux à base de bore et leur utilisation dans le traitement du cancer ou de l'amyloïdose
EP3120836A1 (fr) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Solution de bortezomib prêts à l'emploi
EP3120837A1 (fr) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Solution de bortezomib prêts à l'emploi
CN106478700B (zh) * 2015-08-26 2020-12-29 杭州雷索药业有限公司 硼基取代的苯胺类蛋白激酶抑制剂
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
US11111296B2 (en) 2015-12-14 2021-09-07 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN107151254A (zh) * 2016-03-06 2017-09-12 复旦大学 一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CN106008572B (zh) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 一类二肽硼酸化合物及制备方法和用途
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
DK3472149T3 (da) 2016-06-21 2023-11-27 Orion Ophthalmology LLC Heterocykliske prolinamidderivater
JP6681284B2 (ja) * 2016-06-23 2020-04-15 信越化学工業株式会社 糖アルコール化合物の金属低減方法
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018038687A1 (fr) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Formulations pharmaceutiques comprenant un complexe bortézomib-cyclodextrine
WO2018060833A1 (fr) 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
US20200261596A1 (en) 2016-10-20 2020-08-20 Pfizer Inc. Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP4046989A1 (fr) 2017-01-09 2022-08-24 Shuttle Pharmaceuticals, Inc. Inhibiteurs sélectifs d'histone désacétylase pour le traitement de maladies humaines
WO2018150386A1 (fr) 2017-02-17 2018-08-23 Fresenius Kabi Oncology Ltd. Procédé amélioré pour la préparation d'esters d'acide boronique
WO2018160717A1 (fr) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Composés et méthodes de traitement du cancer
EP3672586A1 (fr) 2017-08-23 2020-07-01 Kezar Life Sciences Inhibiteurs d'immunoprotéasome et agent immunosuppresseur dans le traitement de troubles auto-immuns
CA3075714A1 (fr) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Polytherapie pour le traitement du cancer
JP2018024694A (ja) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
MX2020005036A (es) 2017-11-16 2020-08-17 Principia Biopharma Inc Inhibidores de inmunoproteasoma.
MA50906A (fr) 2017-11-16 2020-09-23 Principia Biopharma Inc Inhibiteurs d'immunoprotéasome
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN111867573A (zh) 2018-01-29 2020-10-30 科诺斯治疗学公司 硼替佐米的瘤内递送
TW202003553A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療癌症之abbv-621與抗癌劑之組合
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2020092395A1 (fr) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. Formes solides de (4-(2-fluoro-4-(1-méthyl-1h-benzo[d]imidazol-5-yl)benzoyl)pipérazin-1-yl)(1-hydroxycyclopropyl)méthanone
CN109824756B (zh) * 2019-03-19 2022-03-22 山东大学 含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
JP2020079299A (ja) * 2020-02-18 2020-05-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
CN114437119B (zh) * 2020-10-30 2024-08-09 苏州开拓药业股份有限公司 一种c-Myc蛋白抑制剂及其制备方法和用途
JP2023553011A (ja) * 2020-12-02 2023-12-20 ホフマン・テクノロジーズ・エルエルシー 非ヒト哺乳動物においてがんを調節するための組成物および方法
EP4242213A4 (fr) * 2020-12-10 2024-05-08 Lg Chem, Ltd. Composé d'acide borique
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
EP4134083A1 (fr) 2021-08-12 2023-02-15 Extrovis AG Compositions pharmaceutiques de bortézomib
CN113957441B (zh) * 2021-10-29 2024-01-02 光华科学技术研究院(广东)有限公司 蚀刻液及其制备方法和应用
KR20250008774A (ko) 2022-05-11 2025-01-15 셀진 코포레이션 T 세포 요법 및 그의 생산과 관련된 방법 및 용도
WO2023220655A1 (fr) 2022-05-11 2023-11-16 Celgene Corporation Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
EP4611798A1 (fr) 2022-11-02 2025-09-10 Celgene Corporation Méthodes de traitement au moyen d'une thérapie par lymphocytes t et d'une thérapie d'entretien par agent immunomodulateur

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261868A (en) * 1979-08-08 1981-04-14 Lever Brothers Company Stabilized enzymatic liquid detergent composition containing a polyalkanolamine and a boron compound
US4369183A (en) * 1979-09-06 1983-01-18 Merck & Co., Inc. 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
US4510130A (en) 1983-05-20 1985-04-09 Genetic Diagnostics Corporation Promoting animal and plant growth with leupeptin
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537707A (en) * 1984-05-14 1985-08-27 The Procter & Gamble Company Liquid detergents containing boric acid and formate to stabilize enzymes
US4842769A (en) * 1985-07-26 1989-06-27 Colgate-Palmolive Co. Stabilized fabric softening built detergent composition containing enzymes
US4759032A (en) 1987-06-03 1988-07-19 Monsanto Company Electrode seal assembly
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) * 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
SE8702550D0 (sv) * 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
WO1988010265A1 (fr) 1987-06-19 1988-12-29 The Regents Of The University Of California Nouvelle classe d'edulcorants a base de proteine a faible taux de calories
EP0315574A3 (fr) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Inhibiteurs de la rénine
US4963655A (en) * 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US4959179A (en) * 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
US5030378A (en) * 1990-01-02 1991-07-09 The Procter & Gamble Company Liquid detergents containing anionic surfactant, builder and proteolytic enzyme
IL97428A0 (en) 1990-03-05 1992-06-21 Cephalon Inc Chymotrypsin-like proteases and their inhibitors
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
EP0478050A1 (fr) * 1990-09-24 1992-04-01 Unilever N.V. Composition détergente
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
CA2098609A1 (fr) * 1990-12-28 1992-06-29 Raymond T. Bartus Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
CA2098702A1 (fr) * 1990-12-28 1992-06-29 James C. Powers Cetoamides, cetoacides et cetoesters de nature peptidique
CA2109526C (fr) * 1991-04-30 1998-01-20 Dwight M. Peterson Detergents liquides renfermant de l'acide arylboronique
ES2085024T3 (es) * 1991-04-30 1996-05-16 Procter & Gamble Detergentes liquidos reforzados con complejo de acido borico-poliol para inhibir la enzima proteolitica.
EP0511456A1 (fr) * 1991-04-30 1992-11-04 The Procter & Gamble Company Détergents liquides contenant un ester aromatique de l'acide borique pour inhibition d'enzyme protéolitique
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
EP0636143B1 (fr) * 1992-04-16 1997-09-24 Zeneca Limited Peptides d'acide alpha-aminoboronique et leur utilisation comme inhibiteurs d'elastase
AU4077193A (en) * 1992-04-16 1993-11-18 Zeneca Limited Alpha-aminoboronic acid peptides and their use as elastase inhibitors
EP0583536B1 (fr) * 1992-08-14 1997-03-05 The Procter & Gamble Company Compositions détergents liquides contenant de l'acide borique
AU676721B2 (en) 1993-02-10 1997-03-20 Dana-Farber Cancer Institute Role of ATP-ubiquitin-dependent proteolysis in MHC-1 restricted antigen presentation and inhibitors thereof
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
DE4311835A1 (de) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
US5424904A (en) * 1993-10-04 1995-06-13 Taylor, Sr.; Thomas T. Circuit for electrically controlled intermittent motion
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5550262A (en) * 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
CA2435124A1 (fr) * 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation de composes d'acide boronique
RS65253B1 (sr) * 2004-03-30 2024-03-29 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline

Also Published As

Publication number Publication date
NL300151I1 (nl) 2004-08-02
NZ296717A (en) 1999-11-29
EP1312609B1 (fr) 2005-12-28
CN1305475C (zh) 2007-03-21
US20150072942A1 (en) 2015-03-12
US20040167332A1 (en) 2004-08-26
CA2203936C (fr) 2005-04-12
WO1996013266A1 (fr) 1996-05-09
EP0788360B3 (fr) 2009-08-12
NL300151I2 (nl) 2004-09-01
ATE411324T1 (de) 2008-10-15
ES2254803T3 (es) 2006-06-16
NZ337211A (en) 2000-12-22
KR970706824A (ko) 1997-12-01
US20110306560A1 (en) 2011-12-15
PT1627880E (pt) 2009-01-23
EP1627880A1 (fr) 2006-02-22
AU4139896A (en) 1996-05-23
DK0788360T3 (da) 2003-09-22
US20030199561A1 (en) 2003-10-23
IL115790A (en) 2002-12-01
ES2314540T3 (es) 2009-03-16
CA2496538C (fr) 2011-08-02
AU710564C (en) 1996-05-23
DK0788360T5 (da) 2017-09-18
US6617317B1 (en) 2003-09-09
DE122004000025I1 (de) 2004-09-30
US20020173488A1 (en) 2002-11-21
JP3717934B2 (ja) 2005-11-16
CN101077875A (zh) 2007-11-28
CN101077875B (zh) 2011-01-26
IL115790A0 (en) 1996-01-19
US6465433B1 (en) 2002-10-15
US20060122390A1 (en) 2006-06-08
ATE314378T1 (de) 2006-01-15
DE69535866D1 (de) 2008-11-27
IL137726A (en) 2004-08-31
EP0788360A1 (fr) 1997-08-13
DE69530936C5 (de) 2007-02-22
CN1168633A (zh) 1997-12-24
FI114801B (fi) 2004-12-31
US7531526B2 (en) 2009-05-12
ES2199257T7 (es) 2010-03-31
IL137726A0 (en) 2001-10-31
CA2496538A1 (fr) 1996-05-09
NO2004004I1 (no) 2004-08-06
DE69534727D1 (de) 2006-02-02
US6083903A (en) 2000-07-04
EP1627880B1 (fr) 2008-10-15
IL133831A (en) 2004-03-28
JPH10510245A (ja) 1998-10-06
HK1002059A1 (en) 1998-07-31
IL133831A0 (en) 2001-04-30
DE69534727T2 (de) 2006-09-14
ES2199257T3 (es) 2004-02-16
US6747150B2 (en) 2004-06-08
FR04C0014I1 (fr) 2004-09-17
FI971746L (fi) 1997-06-06
NO971929D0 (no) 1997-04-25
FI20041415L (fi) 2004-11-03
FI120974B (fi) 2010-05-31
AU710564B2 (en) 1999-09-23
DK1312609T3 (da) 2006-05-15
TW318850B (fr) 1997-11-01
FI971746A0 (fi) 1997-04-23
DE122004000025I2 (de) 2006-09-07
US20070282100A1 (en) 2007-12-06
US7119080B2 (en) 2006-10-10
KR100398944B1 (ko) 2004-06-04
US6066730A (en) 2000-05-23
HK1087714A1 (en) 2006-10-20
CH0788360H1 (de) 2006-03-15
PT788360E (pt) 2003-10-31
EP1997823A1 (fr) 2008-12-03
DK1627880T3 (da) 2008-12-08
NO310558B1 (no) 2001-07-23
CA2203936A1 (fr) 1996-05-09
NO971929L (no) 1997-06-12
US5780454A (en) 1998-07-14
EP0788360A4 (fr) 1998-05-06
MX9703063A (es) 1998-07-31
EP0788360B1 (fr) 2003-05-28
NO2004004I2 (no) 2007-09-10
DE69530936T2 (de) 2004-02-26
US6297217B1 (en) 2001-10-02
US20080132678A1 (en) 2008-06-05
EP1312609A1 (fr) 2003-05-21
LU91083I9 (fr) 2018-12-28
US20090247731A1 (en) 2009-10-01
US8003791B2 (en) 2011-08-23
DE69530936T3 (de) 2010-08-26
PT1312609E (pt) 2006-05-31
US20130310320A1 (en) 2013-11-21
FR04C0014I2 (fr) 2005-05-21
CY2484B1 (en) 2005-06-03
US8378099B2 (en) 2013-02-19
US6548668B2 (en) 2003-04-15
DE69530936D1 (de) 2003-07-03
ATE241631T1 (de) 2003-06-15

Similar Documents

Publication Publication Date Title
LU91083I2 (fr) Bortezomib ou un des ester pharmaceutiquement acceptables, optionnellement sous forme d'un sel pharmaceutiquement acceptable-Velcade.
IL116122A0 (en) Intermediates to heterocyclic-cyclic amine derivatives
DK0490823T3 (fr)
CA2334730A1 (fr) Nouvelles cyclosporines
LU90468I2 (fr) Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
HUP9903174A2 (hu) Koenzim Q-10-et tartalmazó gyógyászati készítmény
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
CA2091343A1 (fr) Methode de preparation de formoterol et de composes apparentes
BG102589A (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
IL134263A0 (en) Use of phanquinone for the treatment of alzheimer's disease
IL105276A (en) (S)-a-PHENYL- 2-PYRIDINEETHANAMINE, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
FI891473A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-aryyli-4-piperidiinikarbinolien valmistamiseksi
EA199800102A1 (ru) Получение производных бициклогексана
CA2078700A1 (fr) Imidazolylmethyl-pyridines
DK0623620T3 (da) 5-HT3-pyrrolopyrazinderivater
ITTO920755A1 (it) Perfezionamenti in macchine per l'assottigliamento periferico di pezzi per calzature.
AU1067795A (en) Use of lithium compounds in the treatment and prevention of alzheimer's disease
PL298827A1 (en) Novel enantiomers derivatives of (s)-2-amino(3,4-dichlorobenzyl) propanol-1
ITMI930017A0 (it) Composizione polimerizzabile per l'impreganzione di un supporto tessile, avente elevate caratteristiche tixotropiche
TH8462S1 (th) ส่วนหนีบจับในเครื่องจักรกล
ITTO910838A1 (it) Apparato portatile per l'auscultazione di suoni.